Guidelines and literature
Oncology and PET/CT Gallery
- 2018
Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis.
Albertsson, P., Alverbratt, C., Liljegren, A., Björkander, E., Strandell, A., Samuelsson, O., . . . Hallqvist, A. (2018). Positron emission tomography and computed tomographic (PET/CT) imaging for radiation therapy planning in anal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol, 126, 6-12. doi:10.1016/j.critrevonc.2018.03.013
- 2018
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.
Dührsen, U., Müller, S., Hertenstein, B., Thomssen, H., Kotzerke, J., Mesters, R., . . . Hüttmann, A. (2018). Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol, 36(20), 2024-2034. doi:10.1200/jco.2017.76.8093
- 2018
Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis.
Hu, J. H., Tang, J. H., Lin, C. H., Chu, Y. Y., & Liu, N. J. (2018). Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis. J Investig Med, 66(1), 52-61. doi:10.1136/jim-2017-000472
- 2018
Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis.
Wang, H., Shen, G., Jiang, C., Li, L., Cui, F., & Tian, R. (2018). Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis. PLOS ONE, 13(3), e0194435. doi:10.1371/journal.pone.0194435
- 2018
Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis.
Wang, H., Shen, G., Jiang, C., Li, L., Cui, F., & Tian, R. (2018). Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis. PLOS ONE, 13(3), e0194435. doi:10.1371/journal.pone.0194435
- 2018
Prognostic value of the maximum standardized uptake value of pre-treatment primary lesions in small-cell lung cancer on 18F-FDG PET/CT: a meta-analysis.
Zhu, D., Wang, Y., Wang, L., Chen, J., Byanju, S., Zhang, H., & Liao, M. (2018). Prognostic value of the maximum standardized uptake value of pre-treatment primary lesions in small-cell lung cancer on 18F-FDG PET/CT: a meta-analysis. Acta Radiol, 59(9), 1082-1090. doi:10.1177/0284185117745907
- 2018
Prognostic value of volume-based metabolic parameters of 18F-FDG PET/CT in ovarian cancer: a systematic review and meta-analysis.
Han, S., Kim, H., Kim, Y. J., Suh, C. H., & Woo, S. (2018a). Prognostic value of volume-based metabolic parameters of (18)F-FDG PET/CT in ovarian cancer: a systematic review and meta-analysis. Ann Nucl Med, 32(10), 669-677. doi:10.1007/s12149-018-1289-1
- 2018
Prognostic Value of Volume-Based Metabolic Parameters of 18F-FDG PET/CT in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis.
Han, S., Kim, H., Kim, Y. J., Suh, C. H., & Woo, S. (2018b). Prognostic Value of Volume-Based Metabolic Parameters of (18)F-FDG PET/CT in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol, 211(5), 1112-1121. doi:10.2214/ajr.18.19734
- 2018
Prognostic Value of Volumetric Parameters of Pretreatment 18F-FDG PET/CT in Esophageal Cancer: A Systematic Review and Meta-analysis.
Han, S., Kim, Y. J., Woo, S., Suh, C. H., & Lee, J. J. (2018). Prognostic Value of Volumetric Parameters of Pretreatment 18F-FDG PET/CT in Esophageal Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med, 43(12), 887-894. doi:10.1097/rlu.0000000000002291
- 2018
Role of Fludeoxyglucose in Breast Cancer: Treatment Response.
Groheux, D. (2018). Role of Fludeoxyglucose in Breast Cancer: Treatment Response. PET Clin, 13(3), 395-414. doi:10.1016/j.cpet.2018.02.003
- 2018
Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis.
Lin, C. Y., Lin, C. L., & Kao, C. H. (2018). Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis. Eur J Radiol, 107, 158-165. doi:10.1016/j.ejrad.2018.09.003
- 2018
THE RELATIONSHIP OF BRAFV600E MUTATION STATUS TO FDG PET/CT AVIDITY IN THYROID CANCER: A REVIEW AND META-ANALYSIS.
Santhanam, P., Khthir, R., Solnes, L. B., & Ladenson, P. W. (2018). THE RELATIONSHIP OF BRAF(V600E) MUTATION STATUS TO FDG PET/CT AVIDITY IN THYROID CANCER: A REVIEW AND META-ANALYSIS. Endocr Pract, 24(1), 21-26. doi:10.4158/ep-2017-0080
- 2018
The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms.
Montes, A., Fernández, A., Camacho, V., de Quintana, C., Gallego, O., Craven-Bartle, J., . . . Carrió, I. (2017). The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms. Rev Esp Med Nucl Imagen Mol, 36(4), 227-232. doi:10.1016/j.remn.2016.11.005
- 2018
Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer
Soldevilla-Gallardo, I. M.-O., Sevastian S: Villarreal-Garza, Cynthia: Bargalló-Rocha, Enrique: Caro-Sánchez, Claudia HS: Hernández-Ramírez, Rodrigo: Estrada-Lobato, Enrique. (2018). Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer. American journal of nuclear medicine and molecular imaging, 8(5), 341. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261879/pdf/ajnmmi0008-0341....
- 2017
Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas
Moreau, A. G., A. L.: Kryza, D.: Borson-Chazot, F.: Bournaud, C.: Mognetti, T.: Lifante, J. C.: Combemale, P.: Giammarile, F.: Houzard, C. (2017). Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas. Nucl Med Commun, 38(9), 771-779. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28704339: https://insights.ovid.com/pubmed?pmid=28704339. doi:10.1097/MNM.0000000000000708
- 2017
Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts
Donohoe, K. J. C., E. J.: Giammarile, F.: Grady, E.: Greenspan, B. S.: Henkin, R. E.: Millstine, J.: Smith, G. T.: Srinivas, S.: Kauffman, J.: Ahuja, S. (2017). Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts. Journal of Nuclear Medicine, 58(4), 14n-17n. Retrieved from ://WOS:000398249600003.
- 2017
Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA
Bozkurt, M. F. V., Irene: Balogova, Sona: Beheshti, Mohsen: Rubello, Domenico: Decristoforo, Clemens: Ambrosini, Valentina: Kjaer, Andreas: Delgado-Bolton, Roberto: Kunikowska, Jolanta. (2017). Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 44(9), 1588-1601.
- 2017
Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review
Dubreuil, J. S., G.: Bozzetto, J.: Tordo, J.: Djaileb, L.: Berriolo-Riedinger, A.: Leenhardt, J.: Giammarile, F.: Meignan, M.: Skanjeti, A. (2017). Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review. Nucl Med Commun, 38(7), 563-576.
- 2017
18F-FDG-PET/CT of peritoneal tumors: a pictorial essay
Dubreuil, J. G., F.: Giamarille, F.: Rousset, P.: Rubello, D.: Colletti, P. M.: Glehen, O.: Skanjeti, A. (2017). 18F-FDG-PET/CT of peritoneal tumors: a pictorial essay. Nucl Med Commun, 38(1), 1-9. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/27820721. doi:10.1097/MNM.0000000000000613
- 2017
SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?
Maffione, A. M. G., F.: Rubello, D. (2017). SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction? Eur J Nucl Med Mol Imaging, 44(10), 1692-1694. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/28638977: https://link.springer.com/content/pdf/10.1007%2Fs00259-017-3757-6.pdf. doi:10.1007/s00259-017-3757-6
- ‹ previous
- 6 of 11
- next ›